|
1
|
Yates M, Watts RA, Bajema IM, Cid MC,
Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA,
et al: EULAR/ERA-EDTA recommendations for the management of
ANCA-associated vasculitis. Ann Rheum Dis. 75:1583–1594.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Nakazawa D, Masuda S, Tomaru U and Ishizu
A: Pathogenesis and therapeutic interventions for ANCA-associated
vasculitis. Nat Rev Rheumatol. 15:91–101. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Geetha D and Jefferson JA: ANCA-associated
vasculitis: Core curriculum 2020. Am J Kidney Dis. 75:124–137.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sachez-Alamo B, Moi L, Bajema I, Berden A,
Flossmann O, Hruskova Z, Jayne D, Wester-Trejo M, Wallquist C and
Westman K: Long-term outcome of kidney function in patients with
ANCA-associated vasculitis. Nephrol Dial Transplant. 39:1483–1493.
2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rhee RL, Hogan SL, Poulton CJ, McGregor
JA, Landis JR, Falk RJ and Merkel PA: Trends in long-term outcomes
among patients with antineutrophil cytoplasmic antibody-associated
vasculitis with renal disease. Arthritis Rheumatol. 68:1711–1720.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Thomas K and Vassilopoulos D: Infections
and vasculitis. Curr Opin Rheumatol. 29:17–23. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Flossmann O, Berden A, De Groot K, Hagen
C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, et al:
Long-term patient survival in ANCA-associated vasculitis. Ann Rheum
Dis. 70:488–494. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hellmich B, Sanchez-Alamo B, Schirmer JH,
Berti A, Blockmans D, Cid MC, Holle JU, Hollinger N, Karadag O,
Kronbichler A, et al: EULAR recommendations for the management of
ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 83:30–47.
2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sethi S, D'agati VD, Nast CC, Fogo AB, De
Vriese AS, Markowitz GS, Glassock RJ, Fervenza FC, Seshan SV, Rule
A, et al: A proposal for standardized grading of chronic changes in
native kidney biopsy specimens. Kidney Int. 91:787–789.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Srivastava A, Palsson R, Kaze AD, Chen ME,
Palacios P, Sabbisetti V, Betensky RA, Steinman TI, Thadhani RI,
McMahon GM, et al: The prognostic value of histopathologic lesions
in native kidney biopsy specimens: Results from the boston kidney
biopsy cohort study. J Am Soc Nephrol. 29:2213–2224.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Casal Moura M, Fervenza FC, Specks U and
Sethi S: Kidney biopsy chronicity grading in antineutrophil
cytoplasmic antibody-associated vasculitis. Nephrol Dial
Transplant. 37:1710–1721. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kronbichler A, Kerschbaum J, Gründlinger
G, Leierer J, Mayer G and Rudnicki M: Evaluation and validation of
biomarkers in granulomatosis with polyangiitis and microscopic
polyangiitis. Nephrol Dial Transplant. 31:930–936. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Monach PA, Warner RL, Lew R, Tómasson G,
Specks U, Stone JH, Fervenza FC, Hoffman GS, Kallenberg CGM,
Langford CA, et al: Serum biomarkers of disease activity in
longitudinal assessment of patients with ANCA-associated
vasculitis. ACR Open Rheumatol. 4:168–176. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Benichou N, Charles P, Terrier B, Jones
RB, Hiemstra T, Mouthon L, Bajema I, Berden A, Thervet E, Guillevin
L, et al: Proteinuria and hematuria after remission induction are
associated with outcome in ANCA-associated vasculitis. Kidney Int.
103:1144–1155. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang C, Tan F, Fang S, Zhang Y, Duan X,
Fan X and Wang X: Diagnostic value of homocysteine combined with C
cystatin in ANCA-associated renal injury. J Xi'an Jiaotong Univ
(Med Sci). 45:616–620. 2024.(In Chinese).
|
|
16
|
Moran SM, Scott J, Clarkson MR, Conlon N,
Dunne J, Griffin MD, Griffin TP, Groarke E, Holian J, Judge C, et
al: The clinical application of urine soluble CD163 in
ANCA-associated vasculitis. J Am Soc Nephrol. 32:2920–2932.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang M and Li J: Construction and
validation of renal injury prediction model in patients with
anti-neutrophil cytoplasmic antibody associated vasculitis. J Clin
Intern Med. 39:610–613. 2022.
|
|
18
|
Huang X: ANCA associated vasculitis with
AKI: Clinical analysis. Zhejiang University, 2020 (In Chinese).
|
|
19
|
Tao M, Geng M and Li Y: Comprehensive
analysis of iron death subtypes and immune characteristics in
anti-neutrophil cytoplasmic antibody associated vasculitis with
renal injury. J Clin Nephrol. 23:921–931. 2023.
|
|
20
|
Miloslavsky EM, Specks U, Merkel PA, Seo
P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW,
Tchao NK, et al: Clinical outcomes of remission induction therapy
for severe antineutrophil cytoplasmic antibody-associated
vasculitis. Arthritis Rheum. 65:2441–2449. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jennette JC and Nachman PH: ANCA
glomerulonephritis and vasculitis. Clin J Am Soc Nephrol.
12:1680–1691. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pagnoux C, Hogan SL, Chin H, Jennette JC,
Falk RJ, Guillevin L and Nachman PH: Predictors of treatment
resistance and relapse in antineutrophil cytoplasmic
antibody-associated small-vessel vasculitis: Comparison of two
independent cohorts. Arthritis Rheum. 58:2908–2918. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Stone JH, Merkel PA, Spiera R, Seo P,
Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A,
Tchao NK, et al: Rituximab versus cyclophosphamide for
ANCA-associated vasculitis. N Engl J Med. 363:221–232.
2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jones RB, Tervaert JW, Hauser T, Luqmani
R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen
P, et al: Rituximab versus cyclophosphamide in ANCA-associated
renal vasculitis. N Engl J Med. 363:211–220. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jones RB, Furuta S, Tervaert JW, Hauser T,
Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, et
al: Rituximab versus cyclophosphamide in ANCA-associated renal
vasculitis: 2-year results of a randomised trial. Ann Rheum Dis.
74:1178–1182. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dirikgil E, Van Leeuwen JR, Bredewold OW,
Ray A, Jonker JT, Soonawala D, Remmelts HHF, van Dam B, Bos WJ, van
Kooten C, et al: ExploriNg DUrable Remission with Rituximab in
ANCA-associatEd vasculitis (ENDURRANCE trial): Protocol for a
randomised controlled trial. BMJ Open. 12(e061339)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rovin BH, Adler SG, Barratt J, Bridoux F,
Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ,
et al: Executive summary of the KDIGO 2021 guideline for the
management of glomerular diseases. Kidney Int. 100:753–779.
2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Esposito P, Cipriani L and Viazzi F:
Plasma exchange and glucocorticoids in severe ANCA-associated
vasculitis. N Engl J Med. 382:2168–2169. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mansfield N, Hamour S, Habib AM, Tarzi R,
Levy J, Griffith M, Cairns T, Cook HT, Pusey CD and Salama AD:
Prolonged disease-free remission following rituximab and low-dose
cyclophosphamide therapy for renal ANCA-associated vasculitis.
Nephrol Dial Transplant. 26:3280–3286. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chevet B, Cornec D, Casal Moura M,
Cornec-Le Gall E, Fervenza FC, Warrington KJ, Specks U and Berti A:
Diagnosing and treating ANCA-associated vasculitis: An updated
review for clinical practice. Rheumatology (Oxford). 62:1787–1803.
2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gulati K, Edwards H, Prendecki M, Cairns
TD, Condon M, Galliford J, Griffith M, Levy JB, Tam FWK, Tanna A,
et al: Combination treatment with rituximab, low-dose
cyclophosphamide and plasma exchange for severe antineutrophil
cytoplasmic antibody-associated vasculitis. Kidney Int.
100:1316–1324. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Furuta S, Nakagomi D, Kobayashi Y,
Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita
Y, et al: Effect of reduced-dose vs high-dose glucocorticoids added
to rituximab on remission induction in ANCA-associated vasculitis:
A Randomized clinical trial. JAMA. 325:2178–2187. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Smith RM, Jones RB, Specks U, Bond S,
Nodale M, Aljayyousi R, Andrews J, Bruchfeld A, Camilleri B,
Carette S, et al: Rituximab as therapy to induce remission after
relapse in ANCA-associated vasculitis. Ann Rheum Dis. 79:1243–1249.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Gopaluni S, Smith RM, Lewin M, McAlear CA,
Mynard K, Jones RB, Specks U, Merkel PA and Jayne DR: RITAZAREM
Investigators. Rituximab versus azathioprine as therapy for
maintenance of remission for anti-neutrophil cytoplasm
antibody-associated vasculitis (RITAZAREM): Study protocol for a
randomized controlled trial. Trials. 18(112)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chanouzas D, Mcgregor JAG, Nightingale P,
Salama AD, Szpirt WM, Basu N, Morgan MD, Poulton CJ, Draibe JB,
Krarup E, et al: Intravenous pulse methylprednisolone for induction
of remission in severe ANCA associated vasculitis: A multi-center
retrospective cohort study. BMC Nephrol. 20(58)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Walsh M, Faurschou M, Berden A, Flossmann
O, Bajema I, Hoglund P, Smith R, Szpirt W, Westman K, Pusey CD, et
al: Long-term follow-up of cyclophosphamide compared with
azathioprine for initial maintenance therapy in ANCA-associated
vasculitis. Clin J Am Soc Nephrol. 9:1571–1576. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chalkia A and Jayne D: ANCA-associated
vasculitis-treatment standard. Nephrol Dial Transplant. 39:944–955.
2024.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Delestre F, Charles P, Karras A, Pagnoux
C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F, et
al: Rituximab as maintenance therapy for ANCA-associated
vasculitides: pooled analysis and long-term outcome of 277 patients
included in the MAINRITSAN trials. Ann Rheum Dis. 83:233–241.
2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen M, Jayne DRW and Zhao MH: Complement
in ANCA-associated vasculitis: Mechanisms and implications for
management. Nat Rev Nephrol. 13:359–367. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ge S, Zhu X, Xu Q, Wang J, An C, Hu Y,
Yang F, Wang X, Yang Y, Chen S, et al: Neutrophils in
ANCA-associated vasculitis: Mechanisms and implications for
management. Front Pharmacol. 13(957660)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Turgeon D, Bakowsky V, Baldwin C, Cabral
DA, Clements-Baker M, Clifford A, Cohen Tervaert JW, Dehghan N,
Ennis D, Famorca L, et al: CanVasc consensus recommendations for
the use of avacopan in antineutrophil cytoplasm antibody-associated
vasculitis: 2022 addendum. Rheumatology (Oxford). 62:2646–2651.
2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Jayne DRW, Bruchfeld AN, Harper L, Schaier
M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati
I, et al: Randomized trial of C5a receptor inhibitor avacopan in
ANCA-Associated vasculitis. J Am Soc Nephrol. 28:2756–2767.
2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jayne DRW, Merkel PA, Schall TJ and Bekker
P: ADVOCATE Study Group. Avacopan for the treatment of
ANCA-associated vasculitis. N Engl J Med. 384:599–609.
2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Grayson PC and Kaplan MJ: At the Bench:
Neutrophil extracellular traps (NETs) highlight novel aspects of
innate immune system involvement in autoimmune diseases. J Leukoc
Biol. 99:253–264. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Schreiber A, Rousselle A, Becker JU, von
Mässenhausen A, Linkermann A and Kettritz R: Necroptosis controls
NET generation and mediates complement activation, endothelial
damage, and autoimmune vasculitis. Proc Natl Acad Sci USA.
114:E9618–E9625. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sangaletti S, Tripodo C, Chiodoni C,
Guarnotta C, Cappetti B, Casalini P, Piconese S, Parenza M,
Guiducci C, Vitali C and Colombo MP: Neutrophil extracellular traps
mediate transfer of cytoplasmic neutrophil antigens to myeloid
dendritic cells toward ANCA induction and associated autoimmunity.
Blood. 120:3007–3018. 2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hakkim A, Fürnrohr BG, Amann K, Laube B,
Abed UA, Brinkmann V, Herrmann M, Voll RE and Zychlinsky A:
Impairment of neutrophil extracellular trap degradation is
associated with lupus nephritis. Proc Natl Acad Sci USA.
107:9813–9818. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Gattu R, Demory Beckler M and Kesselman
MM: Superiority of avacopan and mepolizumab to glucocorticoid
tapering in the treatment of anti-neutrophil cytoplasmic antibody
(ANCA)-Associated vasculitis: A systematic review. Cureus.
16(e67161)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Gopaluni S, Smith R, Goymer D, Cahill H,
Broadhurst E, Wallin E, McClure M, Chaudhry A and Jayne D:
Alemtuzumab for refractory primary systemic vasculitis-a randomised
controlled dose ranging clinical trial of efficacy and safety
(ALEVIATE). Arthritis Res Ther. 24(81)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Jayne DR, Gaskin G, Rasmussen N,
Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO,
Sinico RA, Stegeman CA, et al: Randomized trial of plasma exchange
or high-dosage methylprednisolone as adjunctive therapy for severe
renal vasculitis. J Am Soc Nephrol. 18:2180–2188. 2007.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Casal Moura M, Crowson CS, Specks U,
Warrington KJ, Zand L, Sethi S and Fervenza FC: PLEX in AAV-GN:
Insights from the meta-analysis results and impact on remission
induction treatment recommendations. Clin Kidney J. 16:432–436.
2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Walsh M, Catapano F, Szpirt W, Thorlund K,
Bruchfeld A, Guillevin L, Haubitz M, Merkel PA, Peh CA, Pusey C and
Jayne D: Plasma exchange for renal vasculitis and idiopathic
rapidly progressive glomerulonephritis: A meta-analysis. Am J
Kidney Dis. 57:566–574. 2011.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Walsh M, Merkel PA, Peh CA, Szpirt WM,
Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, et
al: Plasma exchange and glucocorticoids in severe ANCA-associated
vasculitis. N Engl J Med. 382:622–631. 2020.PubMed/NCBI View Article : Google Scholar
|
